How Much Does Rezdiffra (Resmetirom) Cost in Kentucky in 2026?

Rezdiffra Retail Pricing in Kentucky

The standard cash-pay price for Rezdiffra at Kentucky retail pharmacies sits at $3,500 per month in 2026, matching the national manufacturer list price set by Madrigal Pharmaceuticals. This price applies to both the 80 mg and 100 mg tablet strengths, dispensed as a 30-day supply.

Rezdiffra (resmetirom) received accelerated FDA approval in March 2024 as the first drug specifically indicated for MASH with moderate-to-advanced hepatic fibrosis (stages F2 and F3). The approval was based on histological surrogate endpoints, meaning full approval depends on confirmatory outcomes data. Dosing is weight-based: patients weighing <100 kg take 80 mg once daily, while those at or above 100 kg take 100 mg once daily.

Pricing across Kentucky pharmacies shows little variation. Chains like CVS, Walgreens, and Kroger Pharmacy (which has a strong Kentucky footprint) all price Rezdiffra near the $3,500 list. Independent pharmacies rarely discount specialty drugs below that threshold. The annual cost without any coverage or discount program: $42,000.

That number is steep, but it reflects the drug's position as the only FDA-approved pharmacotherapy for MASH. Before resmetirom, no approved drug existed for this disease. Physicians managed MASH with weight loss, pioglitazone (off-label), vitamin E (off-label), and GLP-1 receptor agonists (under investigation). Resmetirom changed the treatment equation entirely by demonstrating histological improvement in a phase 3 trial (MAESTRO-NASH, N=966) published in the New England Journal of Medicine in 2024.

What MAESTRO-NASH Showed About Resmetirom Efficacy

In the MAESTRO-NASH trial, 25.9% of patients on resmetirom 80 mg and 29.9% on 100 mg achieved MASH resolution with no worsening of fibrosis at 52 weeks, compared to 9.7% on placebo [1]. That trial enrolled adults with biopsy-confirmed MASH and fibrosis stages F1B through F3, though the FDA label restricts the indication to F2-F3.

Fibrosis improvement by at least one stage (without MASH worsening) occurred in 24.2% of the 80 mg group and 25.9% of the 100 mg group, versus 14.2% on placebo [1]. These are histological endpoints confirmed by liver biopsy. The difference may sound modest, but in a disease where no prior drug moved the needle on biopsy, a 10-to-15 percentage point separation from placebo represents a meaningful shift.

Resmetirom also reduced LDL cholesterol by roughly 14% and lowered several liver-specific biomarkers including ALT and hepatic fat fraction measured by MRI-PDFF [1]. The thyroid hormone receptor-beta (THR-beta) agonist mechanism drives both hepatic fat clearance and lipid effects without the cardiac risks associated with nonselective thyroid hormone activation. The Endocrine Society's 2024 clinical commentary noted that resmetirom's selectivity for THR-beta over THR-alpha is what makes it tolerable at therapeutic doses.

Side effects were predominantly gastrointestinal. Diarrhea occurred in 26.5% of patients on the 100 mg dose versus 10.3% on placebo. Nausea affected 18.2% versus 5.4% [1]. Most GI events were mild to moderate and resolved within the first 12 weeks of treatment.

Kentucky Medicaid Does Not Cover Rezdiffra

As of May 2026, Kentucky Medicaid does not include Rezdiffra on its preferred drug list. This affects a significant population. Kentucky has one of the highest Medicaid enrollment rates in the nation, with roughly 1.6 million residents covered through the state's expanded Medicaid program.

The omission is not unique to Kentucky. Most state Medicaid programs have been slow to add Rezdiffra, partly because of its accelerated approval status. Payers often wait for full approval (which requires confirmatory data from the ongoing MAESTRO-OUTCOMES trial) before committing to formulary inclusion. The FDA's accelerated approval pathway allows marketing based on surrogate endpoints, but it also signals to payers that the evidence base is still maturing.

Kentucky Medicaid patients with MASH and fibrosis currently have limited pharmacological options. Pioglitazone, which is generic and costs $10-$30/month, remains accessible. Vitamin E at 800 IU daily is available over the counter. Neither carries an FDA indication for MASH, but both appear in the AASLD practice guidance as options for select patients. GLP-1 receptor agonists like semaglutide are being studied in MASH (the ESSENCE trial showed positive phase 3 results), though they are not yet FDA-approved for that indication.

For Kentucky Medicaid enrollees who want to pursue Rezdiffra specifically, the path requires either an exception request through the Medicaid managed care organization (MCO), enrollment in a clinical trial, or use of Madrigal's patient assistance program, which may cover uninsured or underinsured patients.

Commercial Insurance Coverage in Kentucky

Most major commercial insurers operating in Kentucky do cover Rezdiffra, but with restrictions. Anthem Blue Cross Blue Shield (Kentucky's largest commercial carrier), Humana (headquartered in Louisville), and UnitedHealthcare all require prior authorization before approving the drug.

Typical prior authorization criteria across these plans include a confirmed MASH diagnosis with fibrosis stage F2 or F3 documented by liver biopsy or a validated noninvasive test (FibroScan with LSM ≥8.0 kPa, FIB-4 index, or ELF score). Many plans also require documentation that the patient has attempted lifestyle modification (diet and exercise) for at least 6 months and has an elevated ALT level.

Some plans impose step therapy, requiring a trial of pioglitazone or vitamin E before approving Rezdiffra. This creates friction, since those agents are off-label for MASH and may not be appropriate for every patient. Pioglitazone carries risks of weight gain, edema, and fractures. Vitamin E at high doses has been linked to a small increase in all-cause mortality in some meta-analyses, and the AASLD guidance limits its recommended use to non-diabetic MASH patients.

Copay amounts for commercially insured patients in Kentucky vary widely. On a preferred specialty tier, expect $50-$150/month after meeting the deductible. On a non-preferred tier, copays can run $200-$500/month. High-deductible health plans may expose patients to the full $3,500 until the deductible is met.

The quote from Dr. Zobair Younossi, a leading MASH researcher and chair of the Global NASH Council: "Access to resmetirom will define whether the first targeted therapy for MASH reaches the patients who actually need it, or remains a drug that only a fraction of the diagnosed population can afford."

The Madrigal Pharmaceuticals Savings Card

Madrigal offers the RezConnect savings program for commercially insured patients. Eligible patients may pay as little as $0 per month for Rezdiffra, with Madrigal covering the remainder of the copay up to a specified annual maximum (typically $15,000-$20,000 per year, though terms may change).

Eligibility requirements are straightforward. The patient must have commercial insurance that covers Rezdiffra (even with a high copay). Government-insured patients (Medicare, Medicaid, Tricare, VA) are excluded by federal anti-kickback statutes. The patient must be a U.S. resident and have a valid prescription.

Enrollment works through the prescriber's office or the specialty pharmacy. In Kentucky, the primary specialty pharmacies dispensing Rezdiffra include Accredo (an Express Scripts subsidiary), CVS Specialty, and Optum Specialty Pharmacy. The savings card is applied at the point of dispensing, so the copay reduction appears automatically.

For patients without any insurance, Madrigal's separate patient assistance program (PAP) may provide Rezdiffra at no cost. Income thresholds apply, typically set at 400% of the federal poverty level or below. A Kentucky household of one earning <$60,240/year (2026 FPL guidelines) would generally qualify.

Compounded Resmetirom in Kentucky: Legal but Limited

Compounded resmetirom is legally available in Kentucky through licensed 503A compounding pharmacies. A 503A pharmacy compounds medications based on individual patient prescriptions, operating under state Board of Pharmacy oversight and FDA section 503A of the Federal Food, Drug, and Cosmetic Act.

This is the lowest-cost option. Some 503A pharmacies offer compounded resmetirom at dramatically reduced prices compared to the branded product. However, several important caveats apply.

First, compounded drugs are not FDA-approved. They do not undergo the same manufacturing quality controls, bioequivalence testing, or stability studies as commercially manufactured medications. The FDA has issued guidance stating that compounded drugs should be used only when a commercially available product does not meet a patient's medical needs (e.g., allergy to an inactive ingredient, need for a different dosage form).

Second, insurance plans almost never cover compounded medications. Patients pay cash.

Third, the supply chain for compounded resmetirom active pharmaceutical ingredient (API) is not well-established. Resmetirom is a relatively new molecule, and the number of API suppliers meeting USP-grade standards for compounding is limited.

The Kentucky Board of Pharmacy regulates 503A pharmacies in the state. Kentucky law requires a valid patient-specific prescription for 503A compounding, and the prescriber must document a clinical reason for using a compounded product over the commercially available version. Blanket cost-saving prescriptions without clinical justification exist in a regulatory gray area.

Dr. Paul Kwo, a hepatologist at Stanford who has published on MASH pharmacotherapy, has stated: "Compounded versions of newly approved drugs raise real questions about quality assurance and therapeutic equivalence that clinicians need to discuss honestly with patients."

Telehealth Access to Rezdiffra in Kentucky

Kentucky permits telehealth prescribing of Rezdiffra. The state's telehealth parity law, enacted in 2020, requires commercial insurers to cover telehealth visits at the same rate as in-person visits. This means a Kentucky patient can consult a licensed physician via video, receive a MASH diagnosis workup, and obtain a Rezdiffra prescription without an in-person office visit.

Practical considerations matter here. MASH diagnosis at the F2-F3 stage typically requires either a liver biopsy or a FibroScan (vibration-controlled transient elastography). FibroScan is available at major Kentucky medical centers including the University of Kentucky Medical Center in Lexington and UofL Health in Louisville, as well as some gastroenterology practices in Bowling Green, Owensboro, and Northern Kentucky. A telehealth clinician can order the FibroScan, review results remotely, and then prescribe.

Blood-based noninvasive tests like the FIB-4 index (calculated from age, AST, ALT, and platelet count) and the Enhanced Liver Fibrosis (ELF) test can be ordered through any lab. These are fully compatible with a telehealth workflow. The AASLD guidance on noninvasive assessment supports using these tools for initial fibrosis risk stratification, though biopsy remains the reference standard.

HealthRX offers telehealth consultations with physicians experienced in MASH management who can evaluate Kentucky patients for Rezdiffra candidacy, order appropriate testing, and manage ongoing monitoring including liver function tests at weeks 4, 8, and 12 of treatment per the FDA-approved prescribing information.

Monitoring Costs Add to the Total

The drug price is not the only expense. Rezdiffra's label requires liver function monitoring (AST, ALT, bilirubin) at baseline and periodically during treatment. The clinical trial protocol checked LFTs at weeks 4, 8, and 12, then every 3 months.

A basic hepatic function panel costs $20-$50 out-of-pocket at Kentucky labs (Quest, LabCorp, or hospital labs). FibroScan costs $150-$400 per session without insurance. If the prescriber orders a baseline FibroScan plus two follow-up panels in the first year, monitoring adds $200-$600 to the annual cost.

Lipid panels are also relevant since resmetirom lowers LDL cholesterol. Patients on statins may need dose adjustments. The MAESTRO-NASH data showed a 13.6% LDL reduction with the 100 mg dose at 52 weeks [1], which could allow some patients to reduce statin intensity, partially offsetting medication costs.

How Kentucky Compares to Neighboring States

Rezdiffra's cash price is uniform nationally at $3,500/month because Madrigal sets a single wholesale acquisition cost. Differences between states come down to Medicaid coverage and compounding access.

Among Kentucky's neighbors, Tennessee, Ohio, Indiana, Virginia, West Virginia, and Missouri all lack Medicaid coverage for Rezdiffra as of mid-2026. Compounded resmetirom through 503A pharmacies is available in all these states. Kentucky's position is not an outlier. It reflects the national pattern for a drug still under accelerated approval.

The meaningful variable is commercial insurance penetration. Kentucky's uninsured rate dropped to approximately 4.6% after Medicaid expansion under the ACA, one of the largest coverage gains in the country per KFF data. But the state's high Medicaid reliance (roughly 30% of the population) means a large share of potential MASH patients face the Medicaid coverage gap for Rezdiffra.

MASH prevalence in Kentucky is likely above the national average. The state ranks in the top 10 for adult obesity (36.6% prevalence per CDC BRFSS data) and type 2 diabetes (14.1% prevalence). Both conditions are primary drivers of MASH. An estimated 1 in 5 adults with both obesity and type 2 diabetes may have MASH with significant fibrosis, based on modeling from the 2023 Hepatology meta-analysis that estimated global MASH prevalence at 5.27% in the general population and substantially higher in metabolic risk groups.

Practical Steps to Reduce Your Rezdiffra Cost in Kentucky

Patients and prescribers in Kentucky have several strategies to minimize out-of-pocket spending on Rezdiffra.

If commercially insured: apply for the Madrigal RezConnect savings card before filling the first prescription. Confirm that Rezdiffra is on your plan's specialty formulary by calling the number on the back of your insurance card. Have your prescriber submit prior authorization with liver biopsy or FibroScan results, ALT levels, and documentation of fibrosis stage.

If on Kentucky Medicaid: request an exception or prior authorization through your MCO (Anthem Medicaid, Humana CareSource, Molina, Aetna Better Health, or WellCare). Approval is not guaranteed, but individual exceptions have been granted in other states when the clinical case is strong. Apply simultaneously for Madrigal's patient assistance program.

If uninsured: contact Madrigal's PAP directly at 1-833-RezConnect. Income-eligible patients may receive the drug at no cost. Also ask your prescriber about active clinical trials. The MAESTRO-OUTCOMES trial (NCT05500222) is still enrolling at some U.S. sites, and participation provides the drug free along with comprehensive monitoring.

The per-month cost of Rezdiffra in Kentucky for a commercially insured patient using the savings card: $0 to $50. For a Medicaid patient without an exception: $3,500 or the patient assistance program. The gap between those two numbers is the access problem that Kentucky patients and their physicians must work to close.